SCHEMBL4178265

SCHEMBL4178265

CC(=O)N(Cc1cccc(-c2ccc3ncnc(NCCc4ccccc4)c3c2)c1)C1CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 11/20 0.49
CYP3A4 P08684 10/20 0.49
CLK4 Q9HAZ1 10/20 0.49
CYP2D6 P10635 9/20 0.49
ALDH1A1 P00352 8/20 0.49
HSD17B10 Q99714 8/20 0.49
USP2 O75604 7/20 0.49
CYP2C19 P33261 7/20 0.49
MAPK1 P28482 7/20 0.49
LMNA P02545 5/20 0.49
FYN P06241 1/20 0.49
SRC P12931 1/20 0.49
DYRK1A Q13627 1/20 0.47
IRAK4 Q9NWZ3 1/20 0.47
CCNC P24863 1/20 0.47
CDKN1A P38936 1/20 0.47
CDK8 P49336 1/20 0.47
CDK19 Q9BWU1 1/20 0.47
EGFR P00533 1/20 0.47
APP P05067 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4173657 0.92 CYP1A2 (0.47) CYP1A2CYP3A4CLK4CYP2D6ALDH1A1
SCHEMBL4185510 0.90 FYN (0.48) CYP1A2CYP3A4CLK4CYP2D6ALDH1A1
SCHEMBL4178183 0.90 ALDH1A1 (0.52) CYP1A2CYP3A4CLK4CYP2D6ALDH1A1
SCHEMBL4191535 0.90 FYN (0.48) CYP1A2CYP3A4CLK4CYP2D6ALDH1A1
SCHEMBL4180029 0.90 CYP1A2 (0.48) CYP1A2CYP3A4CLK4CYP2D6ALDH1A1
SCHEMBL4175436 0.89 ALDH1A1 (0.49) CYP1A2CYP3A4CLK4CYP2D6ALDH1A1
SCHEMBL4184696 0.88 MAPK1 (0.45) CYP1A2CYP3A4CLK4CYP2D6ALDH1A1
SCHEMBL4173036 0.88 FYN (0.46) CYP1A2CYP3A4CLK4CYP2D6ALDH1A1
SCHEMBL4177764 0.88 LMNA (0.45) CYP1A2CYP3A4CLK4CYP2D6ALDH1A1
SCHEMBL4181370 0.88 ALDH1A1 (0.49) CYP1A2CYP3A4CLK4CYP2D6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090069320-A1 Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof GRUENENTHAL GMBH (DE) 2009-03-12 US claimed
EP-1996562-A1 SUBSTITUTED 4-AMINO-QUINAZOLINE DERIVATIVES AS REGULATORS OF METABOTROPIC GLUTAMATE RECEPTORS AND THEIR USE FOR PRODUCING DRUGS Grünenthal GmbH (DE) 2008-12-03 EP claimed
WO-2007104560-A1 SUBSTITUTED 4-AMINO-QUINAZOLINE DERIVATIVES AS REGULATORS OF METABOTROPIC GLUTAMATE RECEPTORS AND THEIR USE FOR PRODUCING DRUGS Grünenthal GmbH (DE) 2007-09-20 WO claimed
US-20090069320-A1 Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof GRUENENTHAL GMBH (DE) 2009-03-12 US disclosed
EP-1996562-A1 SUBSTITUTED 4-AMINO-QUINAZOLINE DERIVATIVES AS REGULATORS OF METABOTROPIC GLUTAMATE RECEPTORS AND THEIR USE FOR PRODUCING DRUGS Grünenthal GmbH (DE) 2008-12-03 EP disclosed
WO-2007104560-A1 SUBSTITUTED 4-AMINO-QUINAZOLINE DERIVATIVES AS REGULATORS OF METABOTROPIC GLUTAMATE RECEPTORS AND THEIR USE FOR PRODUCING DRUGS Grünenthal GmbH (DE) 2007-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069320-A1 Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof GRM1, GRIN1, GRM2 CYP1A2 4353/4885CYP3A4 4173/4885CLK4 3820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.